ESR1 and breast carcinoma: We further analyzed the patterns of alternative exon usage among the three breast cancer subtypes by the same method as above, and identified 1,773 exons with differential use exclusively when comparing the ER− HER2− to ER+ HER2− subtypes (Fig. 4A).